Pfizer Research on Long-Acting Growth Hormone RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Friday 6th, March 2026
External Deadline: Wednesday 11th, March 2026
Description
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: February 11, 2026
Geographic Scope: the Asia Pacific region, Australia, Brazil, France, Greece, Italy, Israel, Japan, Saudi Arabia, Spain, Turkey, United Arab Emirates, and the United States
Clinical Area: Endocrinology – Long-acting growth hormone
Link to full RFP: Research on Long-Acting Growth Hormone
Application Due Date: March 11, 2026
Specific Area of Interest: Potential applicants are encouraged to address knowledge gaps and unmet needs related to long-acting growth hormone treatment and follow-up:
- – Evaluate different parameters of long-acting growth hormone treatment vs daily growth hormone, such as clinical effect, adherence and/or pathophysiology, in real world setting
- – Explore novel concepts in monitoring and follow-up with daily and long-acting growth hormone treatment
– Explore novel strategies to address current unmet medical needs in short stature management which could be addressed with long-acting growth hormone treatment.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Talita Honorato Rzeszewicz (talita.honorato-rzeszewicz@pfizer.com).